I-Mab Doses First Patient in Phase 3 Study of Lemzoparlimab for MDS in China

The Phase 3 trial is a randomized, controlled, open-label, multi-center study to evaluate the efficacy and safety of lemzoparlimab in combination with AZA ...

 April 25, 2023 | News

Ascentage Pharma Achieves EU GMP Compliance with Zero Deficiencies

 Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-...

 April 25, 2023 | News

Everest Medicines Launches First-in-Disease Therapy for IgA Nephropathy in China's Hainan Boao Pilot Zone.

The launch of this early-access program in Hainan marks the beginning of a new treatment era for IgA nephropathy in China, where Everest can...

 April 24, 2023 | News

Bridge Biotherapeutics Receives FDA Approval for First-in-Human Study of BBT-207, a 4th Gen EGFR TKI.

  The company has been notified by the FDA that the Phase 1/2 clinical trial may proceed The latest preclinical data explored the antitumor effica...

 April 24, 2023 | News

Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML Extended by FDA

The FDA has extended the Prescription Drug User Fee Act (PDUFA) action date by three months to July 24, 2023 to allow additional time to review requested u...

 April 21, 2023 | News

Veeva Systems Finds Digital Content More Effective Than In-Person Meetings in Biopharma Industry

 Veeva Systems (NYSE: VEEV) today released the latest Veeva Pulse Field Trends Report, the largest analysis of global healthcare professiona...

 April 20, 2023 | News

Hasten Biopharma has secured a US$315 million fundraising round led jointly by CBC Group and Mubadala

CBC Group ("CBC"), Asia's largest healthcare-dedicated investment firm headquartered in Singapore, and Hasten Biopharmaceutic Company Limite...

 April 20, 2023 | News

Roquette Cuts Ribbon on $25 Million Pharmaceutical Innovation Center in the United States

Staffed with a team of highly skilled research, application and  formulation experts, the new $25 million center will be an advanced training and coll...

 April 20, 2023 | News

Ajinomoto Bio-Pharma Services Receives FDA Approval for High Potency Fill Line

"Receiving FDA approval on our HPAPI fill line is an exciting milestone for our company, and couldn't have happened without the hard work, hours of prepara...

 April 20, 2023 | News

HUTCHMED's Fruquintinib NDA Accepted in China for 2nd-Line Gastric Cancer

Dr. Michael Shi, Head of R&D and Chief Medical Officer of HUTCHMED said, “The NMPA acceptance of our NDA for fruquintinib is a positive step towa...

 April 18, 2023 | News

Bridge Bio Announces First Patient Dosed in Phase 2a Trial of BBT-877 for Idiopathic Pulmonary Fibrosis Treatment

In the Phase 1 study in 2019, BBT-877, a potent autotaxin (ATX) inhibitor, demonstrated its ability to inhibit lysophosphatidic acid (LPA) production by as...

 April 13, 2023 | News

Biosyngen received China NMPA IND approval for its T-cell redirection therapy targeting EBV-positive Lymphoma

Currently, commercially available cell therapies, such as CD19 CAR-T, are designed for the treatment of B cell lymphoma or acute lymphoblastic leukemia. Tr...

 April 12, 2023 | News

Thermo Fisher Scientific Expands in France for Enhanced Manufacturing Capabilities.

Thermo Fisher Scientific, the world leader in serving science, is adding early development work for oral solid dose therapies to its Bourgoin, France site,...

 April 06, 2023 | News

Singapore HSA Accepts Everest Medicines' Nefecon Application for IgA Nephropathy Treatment

 Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commerc...

 April 06, 2023 | News


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in